Chemicals
Showing 16651–16800 of 41137 results
-
Damaged DNA in humans is detected by sensor proteins that transmit a signal through checkpoint kinases (Chks) Chk1 and Chk2.{24026} Debromohymenialdisine (DBH) is a marine sponge alkaloid that inhibits Chk1 and Chk2 (IC50 = 3 and 3.5 µM, respectively), blocking G2 arrest.{24024,24029} Because it does not significantly affect the activity of ataxia-telangiectasia mutated (ATM) or ATM-Tad2-related protein, DBH is a useful tool for studying the roles of Chk1 and Chk2 in DNA repair and cell cycle regulation.{24024} DBH also inhibits MAP kinase kinase 1 (IC50 = 881 nM), glycogen synthase kinase 3β (IC50 = 1.39 μM), cyclin-dependent kinase 5/p25 (IC50 = 9.12 μM), protein tyrosine kinase 6 (IC50 = 0.6 μM), and other kinases largely unrelated to DNA damage/repair and cell cycling.{24027,24028,24025,24023}
Brand:CaymanSKU:-
Decamethonium is a depolarizing neuromuscular blocking agent.{42107} It is a partial agonist of muscle-type nicotinic acetylcholine receptors (nAChRs).{42108} Decamethonium activates α1β1-containing adult mouse muscle-type nAChRs expressed in X. laevis oocytes with an EC50 value of 40 µM using voltage clamp electrophysiology. It is also a nondepolarizing antagonist of neuronal-type nAChRs, inhibiting mouse α7-, α3β2-, α3β4-, and α4β2-containing receptors with IC50 values of 7.4, 405, 28, and 59 µM, respectively. Decamethonoium is a competitive antagonist of α4β2-containing nAChRs expressed in SH-EP1 cells (IC50 = 52 µM for the human receptor).{27173} It also inhibits electric eel acetylcholinesterase (AChE) and blocks electrically-evoked tibialis muscle twitches in anesthetized cats with ED95 values of 35 and 70 µg/kg for cats under chloralose and ether anesthesia, respectively.{42107,19407} Formulations containing decamethonium have been used to induce paralysis during anesthesia.
Brand:CaymanSKU:24907 - 1 gAvailable on backorder
Decamethonium is a depolarizing neuromuscular blocking agent.{42107} It is a partial agonist of muscle-type nicotinic acetylcholine receptors (nAChRs).{42108} Decamethonium activates α1β1-containing adult mouse muscle-type nAChRs expressed in X. laevis oocytes with an EC50 value of 40 µM using voltage clamp electrophysiology. It is also a nondepolarizing antagonist of neuronal-type nAChRs, inhibiting mouse α7-, α3β2-, α3β4-, and α4β2-containing receptors with IC50 values of 7.4, 405, 28, and 59 µM, respectively. Decamethonoium is a competitive antagonist of α4β2-containing nAChRs expressed in SH-EP1 cells (IC50 = 52 µM for the human receptor).{27173} It also inhibits electric eel acetylcholinesterase (AChE) and blocks electrically-evoked tibialis muscle twitches in anesthetized cats with ED95 values of 35 and 70 µg/kg for cats under chloralose and ether anesthesia, respectively.{42107,19407} Formulations containing decamethonium have been used to induce paralysis during anesthesia.
Brand:CaymanSKU:24907 - 10 gAvailable on backorder
Decamethonium is a depolarizing neuromuscular blocking agent.{42107} It is a partial agonist of muscle-type nicotinic acetylcholine receptors (nAChRs).{42108} Decamethonium activates α1β1-containing adult mouse muscle-type nAChRs expressed in X. laevis oocytes with an EC50 value of 40 µM using voltage clamp electrophysiology. It is also a nondepolarizing antagonist of neuronal-type nAChRs, inhibiting mouse α7-, α3β2-, α3β4-, and α4β2-containing receptors with IC50 values of 7.4, 405, 28, and 59 µM, respectively. Decamethonoium is a competitive antagonist of α4β2-containing nAChRs expressed in SH-EP1 cells (IC50 = 52 µM for the human receptor).{27173} It also inhibits electric eel acetylcholinesterase (AChE) and blocks electrically-evoked tibialis muscle twitches in anesthetized cats with ED95 values of 35 and 70 µg/kg for cats under chloralose and ether anesthesia, respectively.{42107,19407} Formulations containing decamethonium have been used to induce paralysis during anesthesia.
Brand:CaymanSKU:24907 - 5 gAvailable on backorder
Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:20838 -Out of stock
Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:20838 -Out of stock
Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:20838 -Out of stock
Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:20838 -Out of stock
Decanoic acid methyl ester is an ester form of decanoic acid (Item No. 20838). It has been studied as a single component biodiesel surrogate.{42813}
Brand:CaymanSKU:26864 - 100 gAvailable on backorder
Decanoic acid methyl ester is an ester form of decanoic acid (Item No. 20838). It has been studied as a single component biodiesel surrogate.{42813}
Brand:CaymanSKU:26864 - 250 gAvailable on backorder
Decanoic acid methyl ester is an ester form of decanoic acid (Item No. 20838). It has been studied as a single component biodiesel surrogate.{42813}
Brand:CaymanSKU:26864 - 50 gAvailable on backorder
Decanoic acid methyl ester is an ester form of decanoic acid (Item No. 20838). It has been studied as a single component biodiesel surrogate.{42813}
Brand:CaymanSKU:26864 - 500 gAvailable on backorder
Decanoic acid-d19 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28871 - 10 mgAvailable on backorder
Decanoic acid-d19 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28871 - 100 mgAvailable on backorder
Decanoic acid-d19 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28871 - 250 mgAvailable on backorder
Decanoic acid-d19 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28871 - 50 mgAvailable on backorder
Decanoic acid-d2 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:29409 - 10 mgAvailable on backorder
Decanoic acid-d2 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:29409 - 100 mgAvailable on backorder
Decanoic acid-d2 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:29409 - 50 mgAvailable on backorder
Decanoic acid-d3 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28516 - 10 mgAvailable on backorder
Decanoic acid-d3 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28516 - 100 mgAvailable on backorder
Decanoic acid-d3 is intended for use as an internal standard for the quantification of decanoic acid (Item No. 20838) by GC- or LC-MS. Decanoic acid is a medium-chain saturated fatty acid. It is a non-competitive antagonist at AMPA receptors that selectively reduces glutamate-induced currents in Xenopus oocytes expressing GluA2 and GluA3 subunit-containing AMPA receptors (IC50 = 0.52 mM) over those expressing GluA1 (IC50 = 2.09 mM) or GluA1 and GluA2 subunits (IC50 = 1.16 mM).{47639} It inhibits epileptiform activity induced by pentylenetetrazole (Item No. 18682) or low magnesium in rat hippocampal slices. Decanoic acid (1 mM) induces contractions in isolated guinea pig duodenum, an effect that can be blocked by the muscarinic acetylcholine receptor antagonist hyoscine, voltage-gated sodium channel inhibitor tetrodotoxin (Item Nos. 14964 | 14963), or M2 muscarinic acetylcholine receptor antagonist hexamethonium (Item No. 25505).{47640} It increases the escape threshold in an orofacial mechanical stimulation test in rats when administered at a topical dose of 30% in ointment form, indicating analgesic activity.{47644} This effect can be blocked by the muscarinic acetylcholine receptor antagonist methoctramine (Item No. 24317). Plasma levels of decanoic acid are increased in patients with colorectal cancer when compared to patients with breast cancer or ulcerative colitis or without cancer.{47645}
Brand:CaymanSKU:28516 - 50 mgAvailable on backorder
Decanoyl m-Nitroaniline (DemNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.{8928} FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (arachidonyl ethanolamide; AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DemNA to FAAH activity results in the release of the yellow colorimetric dye m-nitroaniline (ε = 13,500 at 410 nm) This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
Brand:CaymanSKU:90349 - 10 mgAvailable on backorder
Decanoyl m-Nitroaniline (DemNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.{8928} FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (arachidonyl ethanolamide; AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DemNA to FAAH activity results in the release of the yellow colorimetric dye m-nitroaniline (ε = 13,500 at 410 nm) This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
Brand:CaymanSKU:90349 - 25 mgAvailable on backorder
Decanoyl m-Nitroaniline (DemNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.{8928} FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (arachidonyl ethanolamide; AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DemNA to FAAH activity results in the release of the yellow colorimetric dye m-nitroaniline (ε = 13,500 at 410 nm) This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
Brand:CaymanSKU:90349 - 5 mgAvailable on backorder
Decanoyl m-Nitroaniline (DemNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.{8928} FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (arachidonyl ethanolamide; AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DemNA to FAAH activity results in the release of the yellow colorimetric dye m-nitroaniline (ε = 13,500 at 410 nm) This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
Brand:CaymanSKU:90349 - 50 mgAvailable on backorder
Decanoyl-L-carnitine is an ester derivative of L-carnitine (Item No. 21489). It increases the formation of C24 fatty acid intermediates, as well as docosapentaenoic and docosahexaenoic acid (Item No. 90310) in rat hepatocytes.{43578}
Brand:CaymanSKU:26549 - 10 mgAvailable on backorder
Decanoyl-L-carnitine is an ester derivative of L-carnitine (Item No. 21489). It increases the formation of C24 fatty acid intermediates, as well as docosapentaenoic and docosahexaenoic acid (Item No. 90310) in rat hepatocytes.{43578}
Brand:CaymanSKU:26549 - 25 mgAvailable on backorder
Decanoyl-L-carnitine is an ester derivative of L-carnitine (Item No. 21489). It increases the formation of C24 fatty acid intermediates, as well as docosapentaenoic and docosahexaenoic acid (Item No. 90310) in rat hepatocytes.{43578}
Brand:CaymanSKU:26549 - 5 mgAvailable on backorder
Decanoyl-L-carnitine is an ester derivative of L-carnitine (Item No. 21489). It increases the formation of C24 fatty acid intermediates, as well as docosapentaenoic and docosahexaenoic acid (Item No. 90310) in rat hepatocytes.{43578}
Brand:CaymanSKU:26549 - 50 mgAvailable on backorder
Brand:CaymanSKU:29952 - 1 mgAvailable on backorder
Decatromicin B is a bacterial metabolite that has been found in Actinomadura.{43914} It is active against Gram-positive bacteria, including several strains of S. aureus (MICs = 0.39-0.78 µg/ml), two strains of methicillin-resistant S. aureus (MRSA; MICs = 0.39 and 0.78 µg/ml), as well as M. luteus, B. subtilis, and C. bovis (MICs = 0.78, 0.78, and 6.25 µg/ml, respectively).
Brand:CaymanSKU:28132 - 2.5 mgAvailable on backorder
Decatromicin B is a bacterial metabolite that has been found in Actinomadura.{43914} It is active against Gram-positive bacteria, including several strains of S. aureus (MICs = 0.39-0.78 µg/ml), two strains of methicillin-resistant S. aureus (MRSA; MICs = 0.39 and 0.78 µg/ml), as well as M. luteus, B. subtilis, and C. bovis (MICs = 0.78, 0.78, and 6.25 µg/ml, respectively).
Brand:CaymanSKU:28132 - 500 µgAvailable on backorder
5-Azacytidine is an analog of cytidine which can be incorporated into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects.{18356,18373} Decitabine is a 2’-deoxy analog of 5-azacytidine which similarly causes hypomethylation of DNA by inhibiting DNA methyltransferases in a concentration-dependent manner.{18356,18373,17257} This action is useful in conditions characterized by DNA hypermethylation, as is found in myelodysplastic syndromes.{20547}
Brand:CaymanSKU:11166 - 10 mgAvailable on backorder
5-Azacytidine is an analog of cytidine which can be incorporated into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects.{18356,18373} Decitabine is a 2’-deoxy analog of 5-azacytidine which similarly causes hypomethylation of DNA by inhibiting DNA methyltransferases in a concentration-dependent manner.{18356,18373,17257} This action is useful in conditions characterized by DNA hypermethylation, as is found in myelodysplastic syndromes.{20547}
Brand:CaymanSKU:11166 - 25 mgAvailable on backorder
5-Azacytidine is an analog of cytidine which can be incorporated into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects.{18356,18373} Decitabine is a 2’-deoxy analog of 5-azacytidine which similarly causes hypomethylation of DNA by inhibiting DNA methyltransferases in a concentration-dependent manner.{18356,18373,17257} This action is useful in conditions characterized by DNA hypermethylation, as is found in myelodysplastic syndromes.{20547}
Brand:CaymanSKU:11166 - 5 mgAvailable on backorder
5-Azacytidine is an analog of cytidine which can be incorporated into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects.{18356,18373} Decitabine is a 2’-deoxy analog of 5-azacytidine which similarly causes hypomethylation of DNA by inhibiting DNA methyltransferases in a concentration-dependent manner.{18356,18373,17257} This action is useful in conditions characterized by DNA hypermethylation, as is found in myelodysplastic syndromes.{20547}
Brand:CaymanSKU:11166 - 50 mgAvailable on backorder
Decursin is a phytochemical originally isolated from A. gigas with diverse biological activities.{39913,39914,39915,39916,39917} It reduces the growth of B16/F10 murine melanoma cells, but not NIH-3T3 fibroblasts, via induction of apoptosis and increased caspase-3 activity when used at concentrations ranging from 40 to 100 μM.{39913} In vivo, decursin (10 mg/kg, i.p.) reduces tumor growth in a B16/F10 mouse xenograft model. Decursin inhibits RANKL-induced osteoclast differentiation and decreases fusion and migrations of pre-osteoclasts in vitro and prevents LPS-induced bone erosion in mice.{39914} In a mouse model of seizures induced by kainic acid (Item No. 78050), decursin (20 mg/kg) increases latency to the first electroencephalographic (EEG) discharge and attenuates the intensity and reduces the frequency of seizure discharges in the parietal cortex.{39915} Decursin inhibits tube formation and expression of VEGF receptor 2 (VEGFR2) in human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) in vitro and reduces retinal expression of VEGFR2 and neovascularization in rats with diabetes induced by streptozotocin (Item No. 13104).{39916} It also reduces hepatic collagen expression, serum levels of ALT, AST, and ALP, and production of reactive oxygen species (ROS) in a mouse model of CCL4-induced liver fibrosis.{39917}
Brand:CaymanSKU:25214 - 1 mgAvailable on backorder
Decursin is a phytochemical originally isolated from A. gigas with diverse biological activities.{39913,39914,39915,39916,39917} It reduces the growth of B16/F10 murine melanoma cells, but not NIH-3T3 fibroblasts, via induction of apoptosis and increased caspase-3 activity when used at concentrations ranging from 40 to 100 μM.{39913} In vivo, decursin (10 mg/kg, i.p.) reduces tumor growth in a B16/F10 mouse xenograft model. Decursin inhibits RANKL-induced osteoclast differentiation and decreases fusion and migrations of pre-osteoclasts in vitro and prevents LPS-induced bone erosion in mice.{39914} In a mouse model of seizures induced by kainic acid (Item No. 78050), decursin (20 mg/kg) increases latency to the first electroencephalographic (EEG) discharge and attenuates the intensity and reduces the frequency of seizure discharges in the parietal cortex.{39915} Decursin inhibits tube formation and expression of VEGF receptor 2 (VEGFR2) in human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) in vitro and reduces retinal expression of VEGFR2 and neovascularization in rats with diabetes induced by streptozotocin (Item No. 13104).{39916} It also reduces hepatic collagen expression, serum levels of ALT, AST, and ALP, and production of reactive oxygen species (ROS) in a mouse model of CCL4-induced liver fibrosis.{39917}
Brand:CaymanSKU:25214 - 10 mgAvailable on backorder
Decursin is a phytochemical originally isolated from A. gigas with diverse biological activities.{39913,39914,39915,39916,39917} It reduces the growth of B16/F10 murine melanoma cells, but not NIH-3T3 fibroblasts, via induction of apoptosis and increased caspase-3 activity when used at concentrations ranging from 40 to 100 μM.{39913} In vivo, decursin (10 mg/kg, i.p.) reduces tumor growth in a B16/F10 mouse xenograft model. Decursin inhibits RANKL-induced osteoclast differentiation and decreases fusion and migrations of pre-osteoclasts in vitro and prevents LPS-induced bone erosion in mice.{39914} In a mouse model of seizures induced by kainic acid (Item No. 78050), decursin (20 mg/kg) increases latency to the first electroencephalographic (EEG) discharge and attenuates the intensity and reduces the frequency of seizure discharges in the parietal cortex.{39915} Decursin inhibits tube formation and expression of VEGF receptor 2 (VEGFR2) in human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) in vitro and reduces retinal expression of VEGFR2 and neovascularization in rats with diabetes induced by streptozotocin (Item No. 13104).{39916} It also reduces hepatic collagen expression, serum levels of ALT, AST, and ALP, and production of reactive oxygen species (ROS) in a mouse model of CCL4-induced liver fibrosis.{39917}
Brand:CaymanSKU:25214 - 25 mgAvailable on backorder
Decursin is a phytochemical originally isolated from A. gigas with diverse biological activities.{39913,39914,39915,39916,39917} It reduces the growth of B16/F10 murine melanoma cells, but not NIH-3T3 fibroblasts, via induction of apoptosis and increased caspase-3 activity when used at concentrations ranging from 40 to 100 μM.{39913} In vivo, decursin (10 mg/kg, i.p.) reduces tumor growth in a B16/F10 mouse xenograft model. Decursin inhibits RANKL-induced osteoclast differentiation and decreases fusion and migrations of pre-osteoclasts in vitro and prevents LPS-induced bone erosion in mice.{39914} In a mouse model of seizures induced by kainic acid (Item No. 78050), decursin (20 mg/kg) increases latency to the first electroencephalographic (EEG) discharge and attenuates the intensity and reduces the frequency of seizure discharges in the parietal cortex.{39915} Decursin inhibits tube formation and expression of VEGF receptor 2 (VEGFR2) in human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) in vitro and reduces retinal expression of VEGFR2 and neovascularization in rats with diabetes induced by streptozotocin (Item No. 13104).{39916} It also reduces hepatic collagen expression, serum levels of ALT, AST, and ALP, and production of reactive oxygen species (ROS) in a mouse model of CCL4-induced liver fibrosis.{39917}
Brand:CaymanSKU:25214 - 5 mgAvailable on backorder
Decursinol angelate is a pyranocoumarin that has been found in the Korean medicinal herb A. gigas and has diverse biological activities.{42374,42375,42376,42377,42378} It inhibits the growth of K562, HL-60, KG-1, SK-BR-3, AGS, A549, HeLa, HepG2, and G-361 cancer cells (ED50s = 24-56 μM) and decreases estrogen-stimulated growth of MCF-7 breast cancer cells in a concentration-dependent manner via decreased estrogen receptor α (ERα) protein levels and signaling activity.{42374,42375} Decursinol angelate (30 μM) activates PKC purified from rat brain.{42374} It selectively inhibits the cytochrome P450 (CYP) isoform CYP1A1/2 over CYP2D15 and CYP3A12 in canine liver microsomes (Kis = 67.56, 872.5, and 853.9 μM, respectively).{42376} Decursinol angelate (0.01-10 μM) reduces cytotoxicity and malondialdehyde (MDA) production induced by amyloid-β (23-35) (Aβ25-35) and increases superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in PC12 cells.{42377} In mice, decursinol angelate (200 mg/kg) has antinociceptive activity in the tail flick and hot plate tests and reduces acetic acid-induced writhing as well as decreases production of the pro-inflammatory cytokines TNF-α and IL-1β.{42378}
Brand:CaymanSKU:25212 - 1 mgAvailable on backorder
Decursinol angelate is a pyranocoumarin that has been found in the Korean medicinal herb A. gigas and has diverse biological activities.{42374,42375,42376,42377,42378} It inhibits the growth of K562, HL-60, KG-1, SK-BR-3, AGS, A549, HeLa, HepG2, and G-361 cancer cells (ED50s = 24-56 μM) and decreases estrogen-stimulated growth of MCF-7 breast cancer cells in a concentration-dependent manner via decreased estrogen receptor α (ERα) protein levels and signaling activity.{42374,42375} Decursinol angelate (30 μM) activates PKC purified from rat brain.{42374} It selectively inhibits the cytochrome P450 (CYP) isoform CYP1A1/2 over CYP2D15 and CYP3A12 in canine liver microsomes (Kis = 67.56, 872.5, and 853.9 μM, respectively).{42376} Decursinol angelate (0.01-10 μM) reduces cytotoxicity and malondialdehyde (MDA) production induced by amyloid-β (23-35) (Aβ25-35) and increases superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in PC12 cells.{42377} In mice, decursinol angelate (200 mg/kg) has antinociceptive activity in the tail flick and hot plate tests and reduces acetic acid-induced writhing as well as decreases production of the pro-inflammatory cytokines TNF-α and IL-1β.{42378}
Brand:CaymanSKU:25212 - 10 mgAvailable on backorder
Decursinol angelate is a pyranocoumarin that has been found in the Korean medicinal herb A. gigas and has diverse biological activities.{42374,42375,42376,42377,42378} It inhibits the growth of K562, HL-60, KG-1, SK-BR-3, AGS, A549, HeLa, HepG2, and G-361 cancer cells (ED50s = 24-56 μM) and decreases estrogen-stimulated growth of MCF-7 breast cancer cells in a concentration-dependent manner via decreased estrogen receptor α (ERα) protein levels and signaling activity.{42374,42375} Decursinol angelate (30 μM) activates PKC purified from rat brain.{42374} It selectively inhibits the cytochrome P450 (CYP) isoform CYP1A1/2 over CYP2D15 and CYP3A12 in canine liver microsomes (Kis = 67.56, 872.5, and 853.9 μM, respectively).{42376} Decursinol angelate (0.01-10 μM) reduces cytotoxicity and malondialdehyde (MDA) production induced by amyloid-β (23-35) (Aβ25-35) and increases superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in PC12 cells.{42377} In mice, decursinol angelate (200 mg/kg) has antinociceptive activity in the tail flick and hot plate tests and reduces acetic acid-induced writhing as well as decreases production of the pro-inflammatory cytokines TNF-α and IL-1β.{42378}
Brand:CaymanSKU:25212 - 25 mgAvailable on backorder
Decursinol angelate is a pyranocoumarin that has been found in the Korean medicinal herb A. gigas and has diverse biological activities.{42374,42375,42376,42377,42378} It inhibits the growth of K562, HL-60, KG-1, SK-BR-3, AGS, A549, HeLa, HepG2, and G-361 cancer cells (ED50s = 24-56 μM) and decreases estrogen-stimulated growth of MCF-7 breast cancer cells in a concentration-dependent manner via decreased estrogen receptor α (ERα) protein levels and signaling activity.{42374,42375} Decursinol angelate (30 μM) activates PKC purified from rat brain.{42374} It selectively inhibits the cytochrome P450 (CYP) isoform CYP1A1/2 over CYP2D15 and CYP3A12 in canine liver microsomes (Kis = 67.56, 872.5, and 853.9 μM, respectively).{42376} Decursinol angelate (0.01-10 μM) reduces cytotoxicity and malondialdehyde (MDA) production induced by amyloid-β (23-35) (Aβ25-35) and increases superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in PC12 cells.{42377} In mice, decursinol angelate (200 mg/kg) has antinociceptive activity in the tail flick and hot plate tests and reduces acetic acid-induced writhing as well as decreases production of the pro-inflammatory cytokines TNF-α and IL-1β.{42378}
Brand:CaymanSKU:25212 - 5 mgAvailable on backorder
Decylubiquinone is an analog of ubiquinone (coenzyme Q10; Item No. 11506). It blocks reactive oxygen species production in response to glutathione depletion and inhibits activation of the mitochondrial permeability transition.{32820} Decylubiquinone inhibited opening of the mitochondrial permeability transition pore in response to calcium overload in rat liver mitochondria in different cell lines at concentrations between 50-100 µM.{30293}
Brand:CaymanSKU:21027 -Out of stock
Decylubiquinone is an analog of ubiquinone (coenzyme Q10; Item No. 11506). It blocks reactive oxygen species production in response to glutathione depletion and inhibits activation of the mitochondrial permeability transition.{32820} Decylubiquinone inhibited opening of the mitochondrial permeability transition pore in response to calcium overload in rat liver mitochondria in different cell lines at concentrations between 50-100 µM.{30293}
Brand:CaymanSKU:21027 -Out of stock
Decylubiquinone is an analog of ubiquinone (coenzyme Q10; Item No. 11506). It blocks reactive oxygen species production in response to glutathione depletion and inhibits activation of the mitochondrial permeability transition.{32820} Decylubiquinone inhibited opening of the mitochondrial permeability transition pore in response to calcium overload in rat liver mitochondria in different cell lines at concentrations between 50-100 µM.{30293}
Brand:CaymanSKU:21027 -Out of stock
Decylubiquinone is an analog of ubiquinone (coenzyme Q10; Item No. 11506). It blocks reactive oxygen species production in response to glutathione depletion and inhibits activation of the mitochondrial permeability transition.{32820} Decylubiquinone inhibited opening of the mitochondrial permeability transition pore in response to calcium overload in rat liver mitochondria in different cell lines at concentrations between 50-100 µM.{30293}
Brand:CaymanSKU:21027 -Out of stock
Decynium-22 is an inhibitor of monoamine transporters and organic cation transporters (OCTs).{48740} It inhibits the plasma membrane monoamine, serotonin (5-HT), norepinephrine, and dopamine monoamine transporters (IC50s = 1.1, 7.9, 30, and 12.9 µM, respectively), and OCT2 and OCT3 (IC50s = 10 and 0.2 µM, respectively) in radioligand binding assays. Decynium-22 also inhibits binding of the α1-adrenergic receptor antagonist prazosin (Item No. 15023) in mouse hippocampal homogenates (IC50 = 60 nM).{48741} It decreases the time stress-sensitive Wistar Kyoto, but not stress-resistant Long-Evans, rats spend immobile in the forced swim test, indicating antidepressant-like activity, when administered at doses of 1 and 10 µg/kg.{48742}
Brand:CaymanSKU:29494 - 1 gAvailable on backorder
Decynium-22 is an inhibitor of monoamine transporters and organic cation transporters (OCTs).{48740} It inhibits the plasma membrane monoamine, serotonin (5-HT), norepinephrine, and dopamine monoamine transporters (IC50s = 1.1, 7.9, 30, and 12.9 µM, respectively), and OCT2 and OCT3 (IC50s = 10 and 0.2 µM, respectively) in radioligand binding assays. Decynium-22 also inhibits binding of the α1-adrenergic receptor antagonist prazosin (Item No. 15023) in mouse hippocampal homogenates (IC50 = 60 nM).{48741} It decreases the time stress-sensitive Wistar Kyoto, but not stress-resistant Long-Evans, rats spend immobile in the forced swim test, indicating antidepressant-like activity, when administered at doses of 1 and 10 µg/kg.{48742}
Brand:CaymanSKU:29494 - 250 mgAvailable on backorder
Decynium-22 is an inhibitor of monoamine transporters and organic cation transporters (OCTs).{48740} It inhibits the plasma membrane monoamine, serotonin (5-HT), norepinephrine, and dopamine monoamine transporters (IC50s = 1.1, 7.9, 30, and 12.9 µM, respectively), and OCT2 and OCT3 (IC50s = 10 and 0.2 µM, respectively) in radioligand binding assays. Decynium-22 also inhibits binding of the α1-adrenergic receptor antagonist prazosin (Item No. 15023) in mouse hippocampal homogenates (IC50 = 60 nM).{48741} It decreases the time stress-sensitive Wistar Kyoto, but not stress-resistant Long-Evans, rats spend immobile in the forced swim test, indicating antidepressant-like activity, when administered at doses of 1 and 10 µg/kg.{48742}
Brand:CaymanSKU:29494 - 500 mgAvailable on backorder
Deethylindanomycin is a polyether antibiotic that has been found in S. setonii.{47369,47370} It is active against a variety of Gram-positive bacteria, including various strains of S. aureus and Streptococcus, as well as one strain of S. pneumoniae (MICs = 4, 4, and 2 µg/ml, respectively).{47370} It is also active against coccidia in vitro, inhibiting E. tenella development, but is inactive against E. tenella infection in chicks when administered at a dose of 200 µg/g in the diet. Deethylindanomycin acts as an ionophore in lipid bilayer membranes and is more selective for potassium ions than calcium, magnesium, and sodium ions.{47369} It induces histamine release from rodent mast cells and human basophils in vitro in a calcium-dependent manner.
Brand:CaymanSKU:28089 - 1 mgAvailable on backorder
Deethylindanomycin is a polyether antibiotic that has been found in S. setonii.{47369,47370} It is active against a variety of Gram-positive bacteria, including various strains of S. aureus and Streptococcus, as well as one strain of S. pneumoniae (MICs = 4, 4, and 2 µg/ml, respectively).{47370} It is also active against coccidia in vitro, inhibiting E. tenella development, but is inactive against E. tenella infection in chicks when administered at a dose of 200 µg/g in the diet. Deethylindanomycin acts as an ionophore in lipid bilayer membranes and is more selective for potassium ions than calcium, magnesium, and sodium ions.{47369} It induces histamine release from rodent mast cells and human basophils in vitro in a calcium-dependent manner.
Brand:CaymanSKU:28089 - 5 mgAvailable on backorder
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays a vital role in many oncogenic pathways.{28867,28866} Defactinib is a dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM.{28865} It is less effective against the related kinase PYK2. Defactinib restores the chemosensitivity of taxane-resistant cells to paclitaxel (Item No. 10461), although it is not cytotoxic alone.{28865} Defactinib decreases YB-1 phosphorylation and nuclear accumulation in an Akt-dependent manner. It is orally bioavailable, inhibiting FAK and augmenting paclitaxel action in suppressing the growth and number of ovarian cancer cell tumors in mice.{28865}
Brand:CaymanSKU:-Available on backorder
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays a vital role in many oncogenic pathways.{28867,28866} Defactinib is a dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM.{28865} It is less effective against the related kinase PYK2. Defactinib restores the chemosensitivity of taxane-resistant cells to paclitaxel (Item No. 10461), although it is not cytotoxic alone.{28865} Defactinib decreases YB-1 phosphorylation and nuclear accumulation in an Akt-dependent manner. It is orally bioavailable, inhibiting FAK and augmenting paclitaxel action in suppressing the growth and number of ovarian cancer cell tumors in mice.{28865}
Brand:CaymanSKU:-Available on backorder
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays a vital role in many oncogenic pathways.{28867,28866} Defactinib is a dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM.{28865} It is less effective against the related kinase PYK2. Defactinib restores the chemosensitivity of taxane-resistant cells to paclitaxel (Item No. 10461), although it is not cytotoxic alone.{28865} Defactinib decreases YB-1 phosphorylation and nuclear accumulation in an Akt-dependent manner. It is orally bioavailable, inhibiting FAK and augmenting paclitaxel action in suppressing the growth and number of ovarian cancer cell tumors in mice.{28865}
Brand:CaymanSKU:-Available on backorder
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays a vital role in many oncogenic pathways.{28867,28866} Defactinib is a dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM.{28865} It is less effective against the related kinase PYK2. Defactinib restores the chemosensitivity of taxane-resistant cells to paclitaxel (Item No. 10461), although it is not cytotoxic alone.{28865} Defactinib decreases YB-1 phosphorylation and nuclear accumulation in an Akt-dependent manner. It is orally bioavailable, inhibiting FAK and augmenting paclitaxel action in suppressing the growth and number of ovarian cancer cell tumors in mice.{28865}
Brand:CaymanSKU:-Available on backorder
Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:-Out of stock
Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:-Out of stock
Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:-Out of stock
Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:-Out of stock
Deferasirox-d4 is intended for use as an internal standard for the quantification of deferasirox (Item No. 16753) by GC- or LC-MS. Deferasirox is a synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:25430 - 1 mgAvailable on backorder
Deferasirox-d4 is intended for use as an internal standard for the quantification of deferasirox (Item No. 16753) by GC- or LC-MS. Deferasirox is a synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 | 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.
Brand:CaymanSKU:25430 - 500 µgAvailable on backorder
Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.{42958} It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 µM, respectively.{42959} Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase-3β (GSK-3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.{42960} Formulations containing deferiprone have been used in the treatment of thalassemia.
Brand:CaymanSKU:20387 -Available on backorder
Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.{42958} It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 µM, respectively.{42959} Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase-3β (GSK-3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.{42960} Formulations containing deferiprone have been used in the treatment of thalassemia.
Brand:CaymanSKU:20387 -Available on backorder
Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.{42958} It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 µM, respectively.{42959} Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase-3β (GSK-3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.{42960} Formulations containing deferiprone have been used in the treatment of thalassemia.
Brand:CaymanSKU:20387 -Available on backorder
Deferiprone-d3 is intended for use as an internal standard for the quantification of deferiprone (Item No. 20387) by GC- or LC-MS. Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.{42958} It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 µM, respectively.{42959} Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase 3β (GSK3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.{42960} Formulations containing deferiprone have been used in the treatment of thalassemia.
Brand:CaymanSKU:28702 - 1 mgAvailable on backorder
Deferoxamine is a bacterial siderophore that chelates iron.{23098} It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 µM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia.{23099,8840,23097} Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.{23096}
Brand:CaymanSKU:- Deferoxamine is a bacterial siderophore that chelates iron.{23098} It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 µM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia.{23099,8840,23097} Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.{23096}
Brand:CaymanSKU:- Deferoxamine is a bacterial siderophore that chelates iron.{23098} It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 µM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia.{23099,8840,23097} Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.{23096}
Brand:CaymanSKU:- Deferoxamine is a bacterial siderophore that chelates iron.{23098} It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 µM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia.{23099,8840,23097} Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.{23096}
Brand:CaymanSKU:-
Deflazacort is a prodrug for the active glucocorticoid 21-desacetyl deflazacort (Item No. 20316). Deflazacort and related glucocorticoids have anti-inflammatory and immunosuppressant effects, as well as benefits in certain muscular dystrophies.{32507,32508,32509}
Brand:CaymanSKU:20386 -Available on backorder
Deflazacort is a prodrug for the active glucocorticoid 21-desacetyl deflazacort (Item No. 20316). Deflazacort and related glucocorticoids have anti-inflammatory and immunosuppressant effects, as well as benefits in certain muscular dystrophies.{32507,32508,32509}
Brand:CaymanSKU:20386 -Available on backorder
Deflazacort is a prodrug for the active glucocorticoid 21-desacetyl deflazacort (Item No. 20316). Deflazacort and related glucocorticoids have anti-inflammatory and immunosuppressant effects, as well as benefits in certain muscular dystrophies.{32507,32508,32509}
Brand:CaymanSKU:20386 -Available on backorder
Deflazacort is a prodrug for the active glucocorticoid 21-desacetyl deflazacort (Item No. 20316). Deflazacort and related glucocorticoids have anti-inflammatory and immunosuppressant effects, as well as benefits in certain muscular dystrophies.{32507,32508,32509}
Brand:CaymanSKU:20386 -Available on backorder
Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:24069 - 10 mgAvailable on backorder
Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:24069 - 25 mgAvailable on backorder
Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:24069 - 5 mgAvailable on backorder
Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:24069 - 50 mgAvailable on backorder
Dehydro amlodipine is a potential impurity found in commercial preparations of amlodipine.{49150,49151} It is a degradation product formed during storage or when amlodipine (Item No. 14838) is subjected to oxidative or acidic conditions or undergoes photo or electrochemical degradation.
Brand:CaymanSKU:26622 - 1 mgAvailable on backorder